

PRESS



RELEASE

INTERVENTIONAL PAIN CENTER | SPORTS & REGENERATIVE MEDICINE | DEPENDENCY TREATMENT

FOR IMMEDIATE RELEASE

Breaking Barriers in Addiction Medicine with Algone

In 2016, there were 94 opioid-related overdose deaths in Alaska. That is a rate of 12.5 deaths per 100,000 persons, compared to the national rate of 13.3 deaths per 100,000 persons. The rate has steadily increased from 8.7 deaths per 100,000 persons in 2010. This was mostly due to an increasing number of heroin-related deaths, which totaled 49 in 2016.

When people hear “addiction medicine” they often, and almost subconsciously, visualize “suboxone clinic”. While this is sometimes the case, it is certainly not in regards to Algone and their addiction specialists, Casey Ploof, ARNP-CARN-AP and Dr. Maria L. Freeman.

Their mission is to break the barriers and erase the stigma that has been built around addiction treatment clinics, in addition to simultaneously painting a more accurate picture of what they are accomplishing and how they are doing it.

Algone's Dependency Treatment offers a comprehensive addiction treatment model, called Medicated Assisted Treatment, or MAT. Evidence has shown that successful treatment of addiction, especially early treatment, often includes both behavior and medication changes. A successful MAT program, such as Algone's, utilizes FDA-approved medications as needed and counseling components. For example, patient-provider motivational counseling to assist in the healing process. For this program to be successful, the patient will need to commit to lifestyle changes (diet, exercise, etc.). These are best met with counseling, group therapy, and/ or support from peers and professionals.

Algone's Dependency Treatment is the “bridge” from addiction to sobriety. These therapies help curb withdrawal symptoms and cravings, which then help release a person from the bondage of dependency on opioids. They will help determine what strategy best suits the patients needs with their vast assortment of treatment options, such as The Bridge Device, Vivitrol, Disulfiram, Naltrexone, Naloxone, Acamprosate, and Suboxone.

They also advocate for the Bridge Device, an FDA approved neurology device that stimulates branches of cranial nerves behind the ear as an aid to reduce symptoms of opioid withdrawal.

About Algone: All of Algone's departments teach the power of change through offering cutting-edge treatments, customized for anyone ready to transform their life. With an exclusive multidisciplinary mindset, their team creates an honest, safe, and respectful environment, dedicated to promoting community health and wellness. While there is a specific department for addiction and dependency, ultimately each of the divisions strive to help individuals who may be struggling with pain, dependency and addiction.

CONTACT: Brandy Gallagher
Marketing Director
marketing@aipcak.com

CONTACT: Kira Boyd
Chief Operating Officer
kboyd@aipcak.com